SAB Biotherapeutics, Inc.
NASDAQ: SABS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Samuel J. Reich
- Employees
- 86
- Headquarters
- Miami Beach, United States
- IPO year
- 2021
- Market cap
- $36.7M
- Website
- https://www.sab.bio
Loading SABS…
Loading profile data…Frequently asked questions about SABS
What does SAB Biotherapeutics, Inc. (SABS) do?
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical developm...
Where does SABS trade?
SAB Biotherapeutics, Inc. (SABS) trades on the NASDAQ.
What sector is SABS in?
SAB Biotherapeutics, Inc. (SABS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of SAB Biotherapeutics, Inc.?
Samuel J. Reich is the chief executive officer of SAB Biotherapeutics, Inc. (SABS).
Where is SAB Biotherapeutics, Inc. headquartered?
SAB Biotherapeutics, Inc. is headquartered in United States.
Does SABS pay a dividend?
SAB Biotherapeutics, Inc. (SABS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SABS go public?
SAB Biotherapeutics, Inc. (SABS) completed its initial public offering in 2021.